Thus, clinical responses are targeted to BRAF or MEK1 (the product of the MAP2K1 gene) inhibitors which have been observed in LCH with MAP2K1 and BRAF V600E mutations (17). This evidence concerns the gene BRAF and Langerhans cell histiocytosis.